Galmed Pharmaceuticals Ltd Dossier
Qualitative Analysis
Business overview
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) is a clinical-stage biopharmaceutical company historically focused on the development of Aramchol, a first-in-class synthetic stearoyl-CoA desaturase 1 (SCD1) inhibitor. While initially developed for non-alcoholic steatohepatitis (NASH) and liver fibrosis, the company has strategically expanded its pipeline to target oncological indications (such as metastatic brain cancers) and cardiometabolic diseases. In addition, Galmed is repositioning itself as a diversified healthcare platform, recently announcing a definitive agreement to acquire Colospan, a gastrointestinal-focused medical technology company.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Acquisition of Colospan Ltd., a clinical-stage medical device company developer of the CG-100 device for reducing anastomotic leaks.
Expected impact: Establishes a commercial-stage medtech footprint, addresses anastomotic leak complications in colorectal surgery, and targets a $6 billion market.
Development and commercialization of a novel sublingual formulation of semaglutide using a proprietary Self-Emulsifying Drug Delivery System (SEDDS) in the form of orally dispersible films.
Expected impact: Provides a non-invasive, transmucosal alternative to injectable and oral GLP-1 therapies, potentially enhancing bioavailability and patient compliance.
Expanding the therapeutic indications of lead compound Aramchol beyond NASH/MASH into oncological indications (such as metastatic brain cancer) and cardiac fibrosis.
Expected impact: Validates Aramchol's mechanism of action as an SCD1 inhibitor in new high-value therapeutic areas.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To diversify Galmed's portfolio into the clinical-stage medical device sector, targeting the colorectal surgery market with Colospan's CG-100 device.
Financial impact: Galmed will pay $2.5 million in cash and issue $2.0 million in ordinary shares at closing, and plans to invest at least $6 million over 24 months to build Colospan's European and Israeli commercial footprint.
Strategic Partnerships
Secures exclusive global rights (excluding certain territories) to develop and commercialize a sublingual semaglutide formulation.
Terms: Includes milestone payments and future royalty payments to be determined in the definitive agreement.
To evaluate Galmed's brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for metastatic brain cancer.
Terms: Not explicitly disclosed.
To evaluate a combination of Aramchol Meglumine and a selective PPARα agonist, identifying a novel metabolic pathway for cardiac fibrosis and heart failure.
Terms: Not explicitly disclosed.